Cessation of smoke exposure improves pediatric CF outcomes: Longitudinal analysis of CF Foundation Patient Registry data.
Secondhand smoke
Smoke exposure
Smoking cessation
Tobacco
Journal
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
ISSN: 1873-5010
Titre abrégé: J Cyst Fibros
Pays: Netherlands
ID NLM: 101128966
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
13
12
2020
revised:
20
05
2021
accepted:
29
06
2021
pubmed:
21
7
2021
medline:
29
1
2022
entrez:
20
7
2021
Statut:
ppublish
Résumé
Tobacco smoke exposure is a major risk factor for the health of children and adolescents with CF. In this study, we assess whether cessation of smoke exposure is associated with improved outcomes in this population. We used annualized and encounter-based data from the U.S. CF Foundation Patient Registry (2006-2018) on all individuals born 1998-2010. The analytical sample included those who ever reported second-hand smoke exposure (daily or weekly), ever lived with a smoker, or ever reported smoking themselves. We used non-linear mixed models for pulmonary exacerbations and linear mixed models for ppFEV The sample included 3,633 individuals contributing 19,629 person-years. Cessation of smoke exposure reduced the odds of a pulmonary exacerbation in 12 months by 17% (OR 0.83, p < 0.001) in the first year of cessation, with an additional 6% decrease (OR 0.94, p = 0.003) for each additional year of cessation. Cessation was associated with improvements in ppFEV Eliminating smoke exposure may reduce pulmonary exacerbations and improve respiratory and nutritional outcomes in children and adolescents with CF. Both smoking cessation and exposure prevention should be prioritized in pediatric CF care.
Sections du résumé
BACKGROUND
Tobacco smoke exposure is a major risk factor for the health of children and adolescents with CF. In this study, we assess whether cessation of smoke exposure is associated with improved outcomes in this population.
METHODS
We used annualized and encounter-based data from the U.S. CF Foundation Patient Registry (2006-2018) on all individuals born 1998-2010. The analytical sample included those who ever reported second-hand smoke exposure (daily or weekly), ever lived with a smoker, or ever reported smoking themselves. We used non-linear mixed models for pulmonary exacerbations and linear mixed models for ppFEV
RESULTS
The sample included 3,633 individuals contributing 19,629 person-years. Cessation of smoke exposure reduced the odds of a pulmonary exacerbation in 12 months by 17% (OR 0.83, p < 0.001) in the first year of cessation, with an additional 6% decrease (OR 0.94, p = 0.003) for each additional year of cessation. Cessation was associated with improvements in ppFEV
CONCLUSION
Eliminating smoke exposure may reduce pulmonary exacerbations and improve respiratory and nutritional outcomes in children and adolescents with CF. Both smoking cessation and exposure prevention should be prioritized in pediatric CF care.
Identifiants
pubmed: 34281808
pii: S1569-1993(21)01301-1
doi: 10.1016/j.jcf.2021.06.014
pmc: PMC8403625
mid: NIHMS1723347
pii:
doi:
Substances chimiques
Tobacco Smoke Pollution
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
618-624Subventions
Organisme : NHLBI NIH HHS
ID : K08 HL140190
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK072482
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL135816
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.
Références
Tob Control. 2009 Feb;18(1):43-6
pubmed: 18936053
J Immunol. 2017 Aug 1;199(3):1170-1183
pubmed: 28667160
Am J Respir Crit Care Med. 2015 Dec 15;192(12):1521-4
pubmed: 26669476
J Cyst Fibros. 2020 Sep;19(5):783-790
pubmed: 32081643
Addiction. 2001 Jun;96(6):891-902
pubmed: 11399220
JAMA. 2008 Jan 30;299(4):417-24
pubmed: 18230779
Environ Health Perspect. 2004 Mar;112(3):392-7
pubmed: 14998759
MMWR Morb Mortal Wkly Rep. 2019 Nov 15;68(45):1013-1019
pubmed: 31725711
J Cyst Fibros. 2012 Jan;11(1):34-9
pubmed: 22000068
Dtsch Arztebl Int. 2020 Jan 6;117(1-2):7-13
pubmed: 32008606
J Pediatr. 2010 Nov;157(5):802-7.e1-3
pubmed: 20580019
Ann Am Thorac Soc. 2015 Aug;12(8):1170-6
pubmed: 26288390
Int J Environ Res Public Health. 2016 Oct 12;13(10):
pubmed: 27754353
J Pediatr. 1992 Feb;120(2 Pt 1):261-4
pubmed: 1735823
Emerg Themes Epidemiol. 2017 Nov 14;14:13
pubmed: 29201130
Annu Rev Med. 2016;67:467-86
pubmed: 26332005
Tanaffos. 2018 Jan;17(1):37-41
pubmed: 30116277
Prev Med. 2019 Jun;123:138-142
pubmed: 30902698
J Cyst Fibros. 2021 Jul;20(4):612-617
pubmed: 33023836
Eur Respir Rev. 2013 Sep 1;22(129):205-16
pubmed: 23997047
MMWR Morb Mortal Wkly Rep. 2015 Feb 6;64(4):103-8
pubmed: 25654612
Vital Health Stat 11. 2002 May;(246):1-190
pubmed: 12043359
Eur Heart J. 2005 Sep;26(17):1765-73
pubmed: 15817606
Pediatr Pulmonol. 2020 Sep;55(9):2330-2340
pubmed: 32511883
Lancet. 2009 May 30;373(9678):1891-904
pubmed: 19403164
Am J Respir Crit Care Med. 2007 Dec 1;176(11):1084-9
pubmed: 17872492
Pediatrics. 2017 Feb;139(2):
pubmed: 28093464
Pediatr Pulmonol. 2015 Aug;50(8):763-70
pubmed: 26061914